166 related articles for article (PubMed ID: 17709554)
1. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.
Adotevi O; Vingert B; Freyburger L; Shrikant P; Lone YC; Quintin-Colonna F; Haicheur N; Amessou M; Herbelin A; Langlade-Demoyen P; Fridman WH; Lemonnier F; Johannes L; Tartour E
J Immunol; 2007 Sep; 179(5):3371-9. PubMed ID: 17709554
[TBL] [Abstract][Full Text] [Related]
2. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
[TBL] [Abstract][Full Text] [Related]
3. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization.
Haicheur N; Benchetrit F; Amessou M; Leclerc C; Falguières T; Fayolle C; Bismuth E; Fridman WH; Johannes L; Tartour E
Int Immunol; 2003 Oct; 15(10):1161-71. PubMed ID: 13679386
[TBL] [Abstract][Full Text] [Related]
4. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
Okazaki S; Iwasaki T; Yuba E; Watarai S
J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
Kim D; Hung CF; Wu TC; Park YM
Vaccine; 2010 Oct; 28(45):7297-305. PubMed ID: 20817010
[TBL] [Abstract][Full Text] [Related]
7. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
[TBL] [Abstract][Full Text] [Related]
10. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
[TBL] [Abstract][Full Text] [Related]
11. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Haicheur N; Bismuth E; Bosset S; Adotevi O; Warnier G; Lacabanne V; Regnault A; Desaymard C; Amigorena S; Ricciardi-Castagnoli P; Goud B; Fridman WH; Johannes L; Tartour E
J Immunol; 2000 Sep; 165(6):3301-8. PubMed ID: 10975847
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
13. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
[TBL] [Abstract][Full Text] [Related]
14. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
16. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
17. Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response.
Liu Z; Lefrançois L
J Immunol; 2004 Oct; 173(7):4324-30. PubMed ID: 15383561
[TBL] [Abstract][Full Text] [Related]
18. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.
Guillonneau C; Mintern JD; Hubert FX; Hurt AC; Besra GS; Porcelli S; Barr IG; Doherty PC; Godfrey DI; Turner SJ
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3330-5. PubMed ID: 19211791
[TBL] [Abstract][Full Text] [Related]
19. NKT cell ligand alpha-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation.
Chung Y; Chang WS; Kim S; Kang CY
Eur J Immunol; 2004 Sep; 34(9):2471-9. PubMed ID: 15307179
[TBL] [Abstract][Full Text] [Related]
20. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
